NCT06806241 Effects of Tranexamic Acid Irrigation on Impacted Third Molar Surgery
| NCT ID | NCT06806241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bezmialem Vakif University |
| Condition | Bleeding |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-01-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.
Eligibility Criteria
Inclusion Criteria: 1. Indicated for the Extraction of Bilaterally Impacted Third Molars with Bone Retention. 2. Systemically healthy patients aged 14-40 years with no bleeding disorders. Exclusion Criteria: 1. Patients with systemic diseases affecting general health. 2. Patients diagnosed with any bleeding disorder. 3. Patients with advanced infection or cysts associated with the impacted tooth.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06806241 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 40 Years, studying Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06806241 currently recruiting?
Yes, NCT06806241 is actively recruiting participants. Contact the research team at tahapergel_05@hotmail.com for enrollment information.
Where is the NCT06806241 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06806241 clinical trial?
NCT06806241 is sponsored by Bezmialem Vakif University. The trial plans to enroll 20 participants.